title: Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on.
authors.forename: J
authors.initials: J
authors.lastname: Mikl
authors.forename: P
authors.initials: P
authors.lastname: Aiginger
authors.forename: K
authors.initials: K
authors.lastname: Czerwenka
authors.forename: E
authors.initials: E
authors.lastname: Kubista
authors.forename: H
authors.initials: H
authors.lastname: Salzer
authors.forename: P
authors.initials: P
authors.lastname: Sevelda
authors.forename: J
authors.initials: J
authors.lastname: Spona
authors.forename: A
authors.initials: A
authors.lastname: Staffen
authors.forename: C C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008593:Menopause; D008727:Methotrexate / Q000627:therapeutic use; D009367:Neoplasm Staging; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate